Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Canadian Immunodeficiency Research Collaborative National Institutes of Health (NIH) |
---|---|
Information provided by: | Canadian Immunodeficiency Research Collaborative |
ClinicalTrials.gov Identifier: | NCT00520897 |
The eradication of HIV by antiretroviral therapy has thus far been elusive. It has been consistently demonstrated that a pool of latently infected, resting CD4+ T cells persists in the majority of HIV-infected individuals receiving antiretroviral therapy in whom plasma viremia has been successfully suppressed for prolonged periods of time; this pool has emerged as the major obstacle in achieving the eradication of HIV. We believe that MK-0518 can further the decay and suppression of HIV-1 in patients who have been virologically suppressed for a prolonged period of time on effective cART (≥ 4 years).
Condition | Intervention | Phase |
---|---|---|
HIV Infections |
Drug: Raltegravir (MK0518) Drug: Placebo Procedure: Leukopheresis Procedure: Sigmoid Biopsy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Crossover Assignment |
Official Title: | Effect of Integrase Inhibitor (MK-0518) on Decay of Low Level Viral Replication in HIV Reservoirs in Infected Individuals Who Initiated Conventional Antiretroviral Therapy During the Chronic Phase of Infection |
Estimated Enrollment: | 30 |
Arms | Assigned Interventions |
---|---|
MK0518 + cART: Experimental
Raltegravir + standard of care combined antiretroviral therapy
|
Drug: Raltegravir (MK0518)
400mg BID; 48 weeks
Procedure: Leukopheresis
Procedure: Sigmoid Biopsy
|
Placebo + cART: Placebo Comparator
Placebo + standard of care combined antiretroviral therapy
|
Drug: Placebo Procedure: Leukopheresis Procedure: Sigmoid Biopsy |
The trial is a prospective, double-blind, randomized, placebo-controlled study with two phases: phase I to 48 weeks and phase II to 96 weeks with the primary analysis at 48 weeks. HIV-infected individuals who are taking their first standard cART regimen for at least four years with complete viral suppression. Upon enrollment, he/she will be randomized to one of two arms: the MK-0518 arm or the control arm. As each participant reaches week 48, he/she will be unblinded and those in the MK-0518 arm will continue taking MK-0518. Based on the results of an interim analysis, the control arm will be rolled over to receive MK-0518 for 48 weeks. After the screening, baseline visits and week 4 safety visit, follow-up visits will occur every 8 weeks for both arms.
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Participant with any of the following abnormal laboratory test results in screening:
Contact: Desmond Persad, M.Sc. | 416-465-0856 ext 226 | desmond.persad@mapleleafmedical.com |
Contact: Roberta Halpenny, B.Sc | 416-465-7936 | rhalpenny@on.aibn.com |
Canada, Ontario | |
Maple Leaf Medical Clinic | |
Toronto, Ontario, Canada, M5B 1L6 |
Principal Investigator: | Mona Loutfy, MD | Women's College Hospital |
Study ID Numbers: | 038-00 |
Study First Received: | August 24, 2007 |
Last Updated: | September 4, 2007 |
ClinicalTrials.gov Identifier: | NCT00520897 |
Health Authority: | Canada: Health Canada |
chronic HIV infection Human Immunodeficiency Virus Treatment Experienced |
Virus Diseases Sexually Transmitted Diseases, Viral HIV Infections Sexually Transmitted Diseases |
Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
Communicable Diseases RNA Virus Infections Slow Virus Diseases |
Immune System Diseases Lentivirus Infections Infection |